Select a medication above to begin.
Attruby
acoramidis
Adult Dosing .
Dosage forms: TAB: 356 mg
transthyretin amyloid cardiomyopathy
- [712 mg PO bid]
- Info: for patients with variant or wild-type disease to reduce cardiovascular death and cardiovascular-associated hospitalization; do not cut/crush/chew tab
renal dosing
- [see below]
- renal impairment: no adjustment
- HD/PD: not defined
hepatic dosing
- [not defined]
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.
Contraindications / Cautions .
- hypersensitivity to drug or ingredient
Drug Interactions .
Overview
acoramidis
transthyretin stabilizer
- UGT1A1 substrate
- UGT1A9 substrate
- UGT2B7 substrate
- CYP2C9 inhibitor, weak
Avoid/Use Alternative
- apalutamide
- bosentan
- butalbital
- carbamazepine
- efavirenz
- encorafenib
- enzalutamide
- fexinidazole
- fosphenytoin
- ivosidenib
- lorlatinib
- lumacaftor/ivacaftor
- methadone
- mitapivat
- mitotane
- nelfinavir
- nevirapine
- oxcarbazepine
- pentobarbital
- phenobarbital
- phenytoin
- primidone
- rifabutin
- rifampin
- ritonavir
- St. John's wort
- telmisartan
- tipranavir
- valproic acid
Monitor/Modify Tx
- aficamten
- celecoxib
- deuruxolitinib
- diclofenac
- fluvastatin
- glimepiride
- torsemide
- warfarin
Adverse Reactions .
Serious Reactions
may occur but none reported
Common Reactions
- diarrhea
- upper abdominal pain
Safety/Monitoring .
Monitoring Parameters
no routine tests recommended
Pregnancy/Lactation .
Pregnancy
Clinical Summary
weigh risk/benefit during pregnancy; inadequate human data available; no known risk of fetal harm based on animal data at 13x and 34x MRHD
Pregnancy Reporting
report pregnancy to BridgeBio at 1-844-550-2246
Lactation
Clinical Summary
weigh risk/benefit while breastfeeding; no human data available to assess risk of infant harm or effects on milk production
Pharmacology .
Metabolism: for acoramidis: glucuronidation; CYP450: unknown; UGT: 1A1, 1A9, 2B7 substrate
Excretion: for acoramidis: urine 68% (<10% unchanged), feces 32% (15% unchanged); Half-life: 6h
Subclass: Cardiac Amyloidosis
Mechanism of Action
for acoramidis: binds and selectively stabilizes transthyretin (TTR) tetramer, reducing amyloid formation and deposit into tissues and organs
Formulary .
No Formulary Selected
Join Now to View Patient Handouts!
Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.
Current Members: Sign In.
Pill Pictures
Join Now to View Pill Pictures!
Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.
Current Members: Sign In.